

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



OrbusNeich Medical Group Holdings Limited

業聚醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6929)

PROFIT WARNING

This announcement is made by OrbusNeich Medical Group Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the information currently available to the Board, for the six months ended June 30, 2024 (the “**Current Period**”), the Group is expected to record a decrease in (i) profit for the period attributable to owners of the Company and (ii) adjusted profit for the period attributable to owners of the Company (non-HKFRS measure^{Note}) by over 20% as compared with that for the six months ended June 30, 2023.

The decrease in profit for the period attributable to owners of the Company and adjusted profit for the period attributable to owners of the Company (non-HKFRS measure) are mainly attributable to the following factors: (i) decrease in revenue by over 3% as a result of the decrease in sales of the Group’s balloons in the United States of America and the People’s Republic of China (the “**PRC**”); (ii) increase in overall operating expenses arising from the expenses incurred by the subsidiaries acquired in late 2023; and (iii) decrease in government grants that support our research and development projects in the PRC.

Note: Adjusted profit for the period attributable to the owners of the Company (non-HKFRS measure) is calculated by excluding the effect of share-based compensation expenses.

As the Company is still in the process of finalizing the unaudited interim results of the Group for the Current Period, the information contained in this announcement is only based on a preliminary assessment by the Board of the information currently available and has not been audited or reviewed by the Company's auditor or the audit committee of the Company. Shareholders and potential investors are advised to read carefully the interim results announcement of the Group which is expected to be released in August 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
OrbusNeich Medical Group Holdings Limited
Mr. David CHIEN
Chairman, Executive Director and Chief Executive Officer

Hong Kong, July 31, 2024

As of the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU and Mr. Wing Shing CHEN as Executive Directors; Mr. Ching Chung John CHOW, Mr. Ting San Peter Lionel LEUNG and Dr. Yi ZHOU as Non-Executive Directors; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.